Bruce C. Trapnell, MS, MD

Assistant Director, Adult Cystic Fibrosis Center

Attending Physician

Pulmonologist - Research, Adult Clinical, Division of Pulmonary Medicine

Professor, UC Department of Pediatrics

Phone 513-636-6361

Fax 513-636-3723

Email bruce.trapnell@cchmc.org

Clinical Interests

Pulmonary alveolar proteinosis; cystic fibrosis; alpha-1 antitrypsin deficiency; other rare lung disorders

Research Interests

Alveolar macrophage function; molecular techniques using gene knockout, transgenic and conditional gene expression mouse models and non-human primates, in vitro and in vivo viral gene transfer, and bone marrow transplantation

Bruce Trapnell, MS, MD received his medical degree from the University of Maryland in 1985, and completed a medical residency at The Ohio State University Hospitals and a fellowship in pulmonary medicine at the Clinical Center of the National Institutes of health, where he then served as Senior Attending Physician. Subsequently, he established the Division of Pulmonary and Virology Studies at Genetic Therapy, Inc., a subsidiary of Novartis, Pharma, serving as Vice President before joining Cincinnati Children’s Hospital Medical Center, where he is now Full Professor.

Dr. Trapnell has conducted lung disease research since his training and has been continuously funded by the NIH since 2001, shortly after his arrival in Cincinnati. He has published over 90 original articles and has trained more than 16 post-doctoral fellows. Dr. Trapnell’s research interests are focused to the pathogenesis and therapy of rare lung diseases and mechanisms by which GM-CSF regulates innate immunity and lung host defense.

Dr. Trapnell is Director of Cincinnati’s Cystic Fibrosis Therapeutics Development Network Center, Assistant Director of the Adult Cystic Fibrosis Care Center, Director of the Rare Lung Diseases Clinical Research Consortium, Scientific Director of the Pulmonary Alveolar Proteinosis Foundation. Dr. Trapnell is the past Scientific Director of the Alpha-1 Foundation, for which he organized and directed the grant program for eight years.

MS: Genetics, The George Washington University, Washington, DC, 1981.

MD:
University of Maryland School of Medicine, Baltimore, MD, 1984.

Residency: Internal Medicine, The Ohio State University Hospitals, Columbus, OH, 1987.

Fellowship: Pulmonary Medicine, Warren Grant Magnuson Clinical Center, National Institutes of Health, Bethesda, MD, 1989.

Certification: Diplomate in Internal Medicine, American Board of Internal Medicine, 1987; Diplomate, National Board of Medical Examiners, 1987; Diplomate in Pulmonary Medicine, American Board of Internal Medicine, 2000 .

Wu H, Suzuki T, Carey B, Trapnell BC, McCormack FX. Keratinocyte growth factor (KGF) augments pulmonary innate immunity through epithelium-driven, GM-CSF dependent paracrine activation of alveolar macrophages. J Biol Chem. 2011 Feb 22.

D'Mello S, Trauernicht A, Ryan A, Bonkowski E, Willson T, Trapnell BC, Frank SJ, Kugasathan S, Denson LA. Innate dysfunction promotes linear growth failure in pediatric Crohn's disease and growth hormone resistance in murine ileitis. Inflamm Bowel Dis. 2011 Feb 18.

Suzuki T, Sakagami T, Young LR, Carey BC, Wood RE, Luisetti M, Wert SE, Rubin BK, Kevill K, Chalk C, Whitsett JA, Stevens C, Nogee LM, Campo I, Trapnell BC. Hereditary pulmonary alveolar proteinosis: pathogenesis, presentation, diagnosis, and therapy. Am J Respir Crit Care Med. 2010 Nov 15;182(10):1292-304. 

Young LR, Vandyke R, Gulleman PM, Inoue Y, Brown KK, Schmidt LS, Linehan WM, Hajjar F, Kinder BW, Trapnell BC, Bissler JJ, Franz DN, McCormack FX. Serum vascular endothelial growth factor-D prospectively distinguishes lymphangioleiomyomatosis from other diseases. Chest. 2010 Sep;138(3):674-81.

Han X, Gilbert S, Groschwitz K, Hogan S, Jurickova I, Trapnell B, Samson C, Gully J. Loss of GM-CSF signalling in non-haematopoietic cells increases NSAID ileal injury. Gut. 2010 Aug;59(8):1066-78. 

Sakagami T, Beck D, Uchida K, Suzuki T, Carey BC, Nakata K, Keller G, Wood RE, Wert SE, Ikegami M, Whitsett JA, Luisetti M, Davies S, Krischer JP, Brody A, Ryckman F, Trapnell BC. Patient-derived granulocyte/macrophage colony-stimulating factor autoantibodies reproduce pulmonary alveolar proteinosis in nonhuman primates. Am J Respir Crit Care Med. 2010 Jul 1;182(1):49-61.

Carey B, Trapnell BC. The molecular basis of pulmonary alveolar proteinosis. Clin Immunol. 2010 May;135(2):223-35. 

Trapnell BC, Maguiness K, Graff GR, Boyd D, Beckmann K, Caras S. Efficacy and safety of Creon 24,000 in subjects with exocrine pancreatic insufficiency due to cystic fibrosis. J Cyst Fibros. 2009 Dec;8(6):370-7 

Trapnell BC, Carey BC, Uchida K, Suzuki T. Pulmonary alveolar proteinosis, a primary immunodeficiency of impaired GM-CSF stimulation of macrophages. Curr Opin Immunol. 2009 Oct;21(5):514-21.

Uchida K, Nakata K, Suzuki T, Luisetti M, Watanabe M, Koch DE, Stevens CA, Beck DC, Denson LA, Carey BC, Keicho N, Krischer JP, Yamada Y, Trapnell BC. Granulocyte/macrophage-colony-stimulating factor autoantibodies and myeloid cell immune functions in healthy subjects. Blood. 2009 Mar 12;113(11):2547-56. 

Role of Anti-GM-CSF Antibodies in Myeloid Cell Function & Innate Immunity. Principal Investigator. National Institutes of Health. Apr 2007 - Mar 2012. #R01 HL085453-01A1.